SCHEMBL15020599

SCHEMBL15020599

COc1ccc(-c2c(C)nn3c(-c4cccc(C(F)(F)F)c4)cc(N(C)CCO)nc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.51
MAPK1 P28482 1/20 0.50
CYP1A2 P05177 1/20 0.48
CRHR1 P34998 3/20 0.43
TDP1 Q9NUW8 1/20 0.41
NR1H4 Q96RI1 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
DYRK3 O43781 1/20 0.39
CCNT1 O60563 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK9 P50750 1/20 0.39
CDK5 Q00535 1/20 0.39
DYRK1A Q13627 1/20 0.39
CDK5R1 Q15078 1/20 0.39
DYRK2 Q92630 1/20 0.39
DYRK1B Q9Y463 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15021448 0.89 MAPT (0.39) MAPTMAPK1CYP1A2TDP1NR1H4
SCHEMBL15021009 0.87 PKM (0.38) MAPTMAPK1CYP1A2TDP1NR1H4
SCHEMBL15020593 0.81 CRHR1 (0.39) CRHR1TRPV1DYRK3CCNT1CCNA2
SCHEMBL257327 0.81 MAPT (0.58) MAPTMAPK1CYP1A2CRHR1TDP1
SCHEMBL15021291 0.80 PKM (0.41) MAPTTRPV1DYRK3CCNT1CCNA2
SCHEMBL15021294 0.79 PKM (0.43) MAPTMAPK1CRHR1
SCHEMBL15020884 0.79 PKM (0.42) CRHR1TRPV1DYRK3CCNT1CCNA2
SCHEMBL15021450 0.78 PKM (0.39) CRHR1TRPV1DYRK3CCNT1CCNA2
SCHEMBL257291 0.76 MAPT (0.47) MAPTMAPK1CYP1A2CRHR1TDP1
SCHEMBL15020747 0.76 MAPT (0.47) MAPTMAPK1CYP1A2CRHR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885MAPK1 519/4885CYP1A2 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.